Technical Articles

In the field of tumor immunotherapy, immune checkpoint inhibitors have achieved great success. However, in addition to drugs that regulate T cell activity, therapies targeting the innate immune system are gradually emerging. The CD47-SIRPα axis is one of the important targets, which has shown great potential in tumor immunotherapy.